Teknova to Join the Nasdaq Biotechnology Index
16 December 2021 - 10:02AM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider
of critical reagents for the development and production of
biopharmaceutical products, including drug therapies, novel
vaccines, and molecular diagnostics, today announced that it will
join the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior
to market open on Monday, December 20, 2021.
The NBI is a major global biotech equity index designed to track
the performance of Nasdaq-listed biotechnology or pharmaceuticals
stocks. Calculated under a modified capitalization-weighted
methodology, the NBI is widely followed and tracked by investors
and Exchange Traded Funds products worldwide. As an NBI company,
Teknova met several eligibility requirements, including minimum
market capitalization, average daily trading volume, and length of
time listed as a public company.
“The Teknova team has successfully executed on several important
milestones since our Initial Public Offering in June 2021, and I’m
proud of their commitment to our mission of accelerating the
development and commercialization of next generation therapies,
vaccines, and diagnostics,” said Stephen Gunstream, President and
CEO of Teknova. “We are honored to join the NBI, which we believe
validates our team’s hard work and progress in delivering value to
all of our stakeholders.”
For more information about the NBI, visit Nasdaq NBI.
About TeknovaTeknova is expediting clinical
breakthroughs in the life sciences by providing custom products and
reagents for bioprocessing, bioproduction, and molecular
diagnostics. With a focus on agility and customization, Teknova
delivers research-grade and GMP products including cell culture
media and supplements, protein and nucleic acid purification
buffers, and molecular biology reagents for a multitude of
established and emerging applications, including cell and gene
therapy, mRNA therapeutics, genomics, and synthetic biology.
Teknova's proprietary processes enable the manufacture and delivery
of high quality, custom, made-to-order products on short turnaround
times and at scale across all stages of development, including
commercialization. For more information about Teknova, visit
www.teknova.com.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-216-1830
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jenn Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Apr 2023 to Apr 2024